InVivo in the News
Published: December 17, 2014
(Spinal News International) InVivo Therapeutics has announced approval from the US Food and Drug Administration (FDA) for an expedited enrolment plan for the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury.View Article
Published: December 16, 2014
FDA News Device Daily Bulletin The FDA has given a green light to expedited enrollment in InVivo Therapeutics’ ongoing clinical trial of the Neuro-Spinal Scaffold in patients with acute spinal cord injury, the company said Tuesday. The five-subject pilot study will capture preliminary safety and efficacy data in support of a larger pivotal study and humanitarian device exemption submission.View Article
Published: October 16, 2014
FDA News Device Daily Bulletin InVivo Therapeutics said Tuesday it has enrolled the first patient in a pilot study of the Neuro-Spinal Scaffold. The device is being evaluated as a treatment for complete traumatic spinal cord injuries. The study — conducted at St. Joseph’s Hospital and Medical Center in Phoenix, Ariz. — will gauge the safety and preliminary efficacy of the scaffold, determined by no worsening of paralysis or sensory motor neurological function, the company said.View Article
The articles contained in this section of the website are written and published by persons not affiliated with InVivo. The views expressed in these articles are those of the author(s) and do not reflect the views of InVivo. Additionally, the information contained in these articles may not be current. InVivo disclaims any obligation to correct or to update the information contained in these articles.